Webcast

Rhinomed Investor Briefing – 17 June

June 17, 2020

Rhinomed Investor Briefing – 17 June

Rhinomed Limited (ASX: RNO) Webcast Replay

Rhinomed Limited (ASX.RNO) is a Melbourne based ASX listed airway technology company that has developed a simple and innovative nasal stent to improve air flow to the lungs and deliver therapeutic agents. 

As a part of our ‘Meet the CEOs’ series, CEO Michael Johnson provides valuable insights to the company, its key markets and industry, and future prospects.

Recorded on 17th June 2020 at 12pm (AEST).

Join the next Meet the CEOs webcast

Speak to our Advisor team about this company

FEATURE SPEAKERS

Michael Johnson

CEO & Managing Director

Rhinomed Limited (ASX.RNO) is a Melbourne based ASX listed airway technology company that has developed a simple and innovative nasal stent to improve air flow to the lungs and deliver therapeutic agents. Rhinomed has established a leading position in sports performance enhancement. as testified by athletes including two-time Tour de France winner Chris Froome. The company has three promising product variants and is also developing applications for the delivery of medical cannabis products for conditions including anxiety, pain. allergies, nausea, anxiety and coughs and colds.

Speak to our Advisor team about this company



By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.